Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
BUSINESS
Chugai’s Q1 Sales Double on Ronapreve Bonanza, Brisk Hemlibra Export
Chugai Pharmaceutical saw its first-quarter revenue more than double in 2022, buoyed by the government purchase of its COVID-19 antibody cocktail Ronapreve (casirivimab + imdevimab). The Roche group company notched up growth even excluding this factor. In January-March, the drug…
To read the full story
Related Article
- Chugai’s Q1 Profit Drops by Half in Pullback from Alexion Settlement Gain
April 28, 2023
- Chugai’s Sales Hit 1-Trillion-Yen Mark in 2022 on New Launches, Ronapreve
February 3, 2023
- Chugai Enjoys Big Surge in H1 Earnings on Strong Uptake of New Launches
July 22, 2022
- Chugai Joins Top Ranks in Japan Sales on Ronapreve Boon, Roche Collaboration
February 14, 2022
- Chugai’s Sales and Profit Rose for 5 Years Running, 1 Trillion Yen-Plus Expected in 2022
February 4, 2022
- Chugai’s 9-Month Sales Up 17.5% on Ronapreve, 42.8 Billion Yen Booked in Govt Purchase
October 25, 2021
- Chugai’s H1 Sales Rise on Growth of Tecentriq, Kadcyla
July 27, 2021
- Chugai’s Q1 Sales Slide 5.9% on Drug Price Cuts, Gx, Frontloaded Actemra Exports
April 23, 2021
- Chugai Closes Book with Double-Digit Earnings Growth on Overseas Sales, Royalties
February 5, 2021
BUSINESS
- Astellas on Track to Hit 30% Margin Goal Early after Strong H1 Scorecards
November 5, 2026
- Nxera Inks US$1.47 Billion Deal with AbbVie for IBD Drug
November 5, 2026
- Kissei Might Revise Midterm Targets as Tavneos Faces Approval Revocation
November 5, 2026
- Boehringer, Lung Cancer Society Launch 5-Year Hernexeos Real-World Study
November 5, 2026
- ASKA Snags Japan Rights to Minghui’s TED Therapy
November 5, 2026
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…